PART1 and neoplasm: The clinical results showed that PART1 is significantly overexpressed in liver cancer (Table 1), thereby indicating that PART1 is unrelated to gender, age, and metastasis of liver cancer but related to tumour size, TNM stage, and BCLC stage.